Charles R. Goulding and Preeti Sulibhavi examine how Stryker's acquisition of Inari Medical is set to transform vascular care ...

Inari Medical (NARI – Research Report) received a Hold rating and price target from William Blair analyst Margaret Kaczor today. The ...

Baird R W cut shares of Inari Medical (NASDAQ:NARI – Free Report) from a strong-buy rating to a hold rating in a research note released on Tuesday morning,Zacks.com reports. Several other equities ...

Inari Medical (NASDAQ:NARI – Free Report) had its price target increased by Piper Sandler from $52.00 to $80.00 in a report issued on Tuesday morning,Benzinga reports. The brokerage currently has a ...

Acquisition expected to strengthen Stryker’s neurovascular business with Inari VTE product portfolio including mechanical thrombectomy solutions for peripheral vascular diseases such as deep vein ...

Fintel reports that on January 8, 2025, BTIG downgraded their outlook for Inari Medical (NasdaqGS:NARI) from Buy to Neutral. Analyst Price Forecast Suggests 14.00% Downside As of December 23, 2024, ...

Stryker (NYSE: SYK), a global leader in medical technologies, has announced its definitive agreement to acquire Inari Medical ...

Medical devices behemoth Stryker agreed to buy Inari Medical for $4.9 billion. Inari stock catapulted Tuesday on the news.

Why the splash? Inari's game-changing clot-removal devices for deep vein thrombosis (DVT) and pulmonary embolism (PE) are a perfect fit for Stryker's neurovascular empire. This move doesn't just pad ...

The FlowTreiver product is used for the treatment of pulmonary embolism. Geographically, the company has its presence across the United States. Read More on NARI: Inari Medical NewsMORE Related ...

Inari Medical, Inc. NARI shares rallied ... such as deep vein thrombosis and pulmonary embolism. This company is expected to post quarterly loss of $0.04 per share in its upcoming report, which ...